News Release Details

SOUTH SAN FRANCISCO, Calif., June 17, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will introduce seven new cadmium metal labeling kits for mass cytometry in Q3. Representing the first of a series of new metal isotopes in development, these new isotopes will empower researchers to easily design and customize larger panels to advance biomarker discovery and therapeutic development.

Mass cytometry is an industry-leading tool for deep interrogation of cellular phenotypes and function in health and disease. Powered by proven Fluidigm® CyTOF® technology, the number of research publications using mass cytometry continues to grow at an accelerated pace, offering new insights in cancer, autoimmune and infectious disease, immunotherapy research and more.

Setting an industry first for highly multiplexed cytometry, researchers have used mass cytometry to simultaneously interrogate more than 50 cell surface and intracellular parameters at a time, all from a single sample tube. By providing 135 unique channels to detect different cellular parameters, Fluidigm mass cytometry systems can meet the needs of researchers today and well into the future.

“We are using highly multiplexed mass cytometry to accelerate the development of novel therapeutic approaches for acute leukemia,” said Greg Behbehani, MD, PhD, Assistant Professor of Internal Medicine at Ohio State University. “Utilizing the new metal tags from Fluidigm, we are developing a 49-marker leukemia panel to identify meaningful cellular biomarkers that correlate with therapeutic resistance and response. Our experience has shown that mass cytometry simplifies the development and implementation of large panel designs for clinical research applications while demonstrating highly comparable results with clinical flow cytometry, offering great promise to improve future health care decisions.” 

“The contributions mass cytometry has been making around the world are truly impressive. In addition to powering hundreds of important peer reviewed publications, mass cytometry has been adopted by multiple consortia and more than 40 clinical trials,” said Chris Linthwaite, President and CEO of Fluidigm. “With the introduction of these new metal isotopes, we are increasing the scalability and flexibility of mass cytometry to deliver powerful new health insights.”

About Fluidigm
Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.

Fluidigm, the Fluidigm logo, and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statement for Fluidigm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the anticipated benefits of newly introduced products and the growth and potential of mass cytometry research. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2018, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.

Contacts:

Media:
Michaeline Bunting
Senior Director, Marketing
650 737 4190
michaeline.bunting@fluidigm.com

Investors:
Agnes Lee
Vice President, Investor Relations
650 416 7423
agnes.lee@fluidigm.com

Source: Fluidigm Corporation